ADPT

SEC source: 0001062993-24-005773 · form4.xml · nonDerivative · entry 1

NEUPERT PETER M · CIK 0001237566 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 154,296

SEC source: 0001062993-24-005772 · form4.xml · derivative · entry 2

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,044

Underlying: Common Stock · 48,044 shares

Expires 2034-03-04

F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year from March 4, 2024, subject to continued service as a director through such vesting dates.

SEC source: 0001062993-24-005772 · form4.xml · nonDerivative · entry 1

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,296

SEC source: 0001062993-24-005770 · form4.xml · derivative · entry 2

GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,044

Underlying: Common Stock · 48,044 shares

Expires 2034-03-04

F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year from March 4, 2024, subject to continued service as a director through such vesting dates.

SEC source: 0001062993-24-005770 · form4.xml · nonDerivative · entry 1

GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,955

SEC source: 0001062993-24-005762 · form4.xml · derivative · entry 4

BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 199,549

Underlying: Common Stock · 199,549 shares

Expires 2034-03-04

F2 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001062993-24-005762 · form4.xml · nonDerivative · entry 1

BENZENO SHARON · CIK 0001780854 · Chief Commercial Ofc Imm Med

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 356,805

SEC source: 0001062993-24-005759 · form4.xml · nonDerivative · entry 1

PETERSON TYCHO · CIK 0001927856 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 547,009

SEC source: 0001062993-24-005757 · form4.xml · derivative · entry 4

BOBULSKY SUSAN · CIK 0001820885 · Chief Commercial Officer, MRD

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 199,549

Underlying: Common Stock · 199,549 shares

Expires 2034-03-04

F2 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001062993-24-005757 · form4.xml · nonDerivative · entry 1

BOBULSKY SUSAN · CIK 0001820885 · Chief Commercial Officer, MRD

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 261,281

SEC source: 0001062993-23-022626 · form4.xml · derivative · entry 2

NEUPERT PETER M · CIK 0001237566 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 100,000 shares

Expires 2023-12-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option vested with respect to 1/4 of the Shares under the grant on the year anniversary of December 23, 2013 and with respect to 1/48 of the Shares under the grant monthly thereafter.

SEC source: 0001062993-23-022626 · form4.xml · nonDerivative · entry 1

NEUPERT PETER M · CIK 0001237566 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 122,968

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-23-021224 · form4.xml · nonDerivative · entry 1

PISKEL KYLE · CIK 0001780662 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,305

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade.

SEC source: 0001062993-23-016018 · form4.xml · nonDerivative · entry 2

SOOD NITIN · CIK 0001877433 · Chief Commercial Officer, MRD

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 214,808

F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2022.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $6.48 to $6.60, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001062993-23-016018 · form4.xml · nonDerivative · entry 1

SOOD NITIN · CIK 0001877433 · Chief Commercial Officer, MRD

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 225,358

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-23-013930 · form4.xml · derivative · entry 4

PETERSON TYCHO · CIK 0001927856 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 447,868

Underlying: Common Stock · 134,961 shares

Expires 2032-06-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2023.

F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on June 1, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001062993-23-013930 · form4.xml · nonDerivative · entry 3

PETERSON TYCHO · CIK 0001927856 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 399,219

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2023.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.00 to $8.34, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001062993-23-013930 · form4.xml · nonDerivative · entry 2

PETERSON TYCHO · CIK 0001927856 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 464,180

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2023.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.00 to $8.34, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001062993-23-013930 · form4.xml · nonDerivative · entry 1

PETERSON TYCHO · CIK 0001927856 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 534,180

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2023.

SEC source: 0001062993-23-013872 · form4.xml · derivative · entry 4

PETERSON TYCHO · CIK 0001927856 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 582,829

Underlying: Common Stock · 14,328 shares

Expires 2032-06-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2023.

F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on June 1, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001062993-23-013872 · form4.xml · nonDerivative · entry 3

PETERSON TYCHO · CIK 0001927856 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 399,219

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2023.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.30 to $8.72, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001062993-23-013872 · form4.xml · nonDerivative · entry 2

PETERSON TYCHO · CIK 0001927856 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 413,547

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2023.

SEC source: 0001062993-23-013872 · form4.xml · nonDerivative · entry 1

PETERSON TYCHO · CIK 0001927856 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 399,219

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2023.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.30 to $8.72, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001062993-23-013030 · form4.xml · nonDerivative · entry 1

PETERSON TYCHO · CIK 0001927856 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 454,891

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-23-009085 · form4.xml · nonDerivative · entry 2

ADAMS R MARK · CIK 0001808905 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 175,361

F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2022.

SEC source: 0001062993-23-009085 · form4.xml · nonDerivative · entry 1

ADAMS R MARK · CIK 0001808905 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 177,669

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-23-008033 · form4.xml · nonDerivative · entry 1

GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,627

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2023.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.41 to $8.55, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001062993-23-006324 · form4.xml · nonDerivative · entry 3

SOOD NITIN · CIK 0001877433 · Chief Commercial Officer, MRD

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 231,010

F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2022.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.25 to $8.89, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001062993-23-006327 · form4.xml · nonDerivative · entry 3

ADAMS R MARK · CIK 0001808905 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 178,486

F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2022.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.245 to $8.89, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001062993-23-006328 · form4.xml · nonDerivative · entry 3

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 139,678

F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2022.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.30 to $8.89, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001062993-23-006324 · form4.xml · derivative · entry 4

SOOD NITIN · CIK 0001877433 · Chief Commercial Officer, MRD

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 199,549

Underlying: Common Stock · 199,549 shares

Expires 2033-03-06

F4 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001062993-23-006324 · form4.xml · nonDerivative · entry 2

SOOD NITIN · CIK 0001877433 · Chief Commercial Officer, MRD

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 240,823

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-23-006324 · form4.xml · nonDerivative · entry 1

SOOD NITIN · CIK 0001877433 · Chief Commercial Officer, MRD

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 247,484

SEC source: 0001062993-23-006336 · form4.xml · derivative · entry 2

OWEN KATEY EINTERZ · CIK 0001852578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,329

Underlying: Common Stock · 23,329 shares

Expires 2033-03-06

F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year from March 4, 2023, subject to continued service as a director through such vesting dates.

SEC source: 0001062993-23-006336 · form4.xml · nonDerivative · entry 1

OWEN KATEY EINTERZ · CIK 0001852578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,907

SEC source: 0001062993-23-006327 · form4.xml · derivative · entry 4

ADAMS R MARK · CIK 0001808905 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,033

Underlying: Common Stock · 133,033 shares

Expires 2033-03-06

F4 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001062993-23-006327 · form4.xml · nonDerivative · entry 2

ADAMS R MARK · CIK 0001808905 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 195,641

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-23-006327 · form4.xml · nonDerivative · entry 1

ADAMS R MARK · CIK 0001808905 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 202,170

SEC source: 0001062993-23-006328 · form4.xml · derivative · entry 4

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 128,599

Underlying: Common Stock · 128,599 shares

Expires 2033-03-06

F4 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001062993-23-006328 · form4.xml · nonDerivative · entry 2

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 153,065

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-23-006328 · form4.xml · nonDerivative · entry 1

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 158,556

SEC source: 0001062993-23-006321 · form4.xml · nonDerivative · entry 1

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,270,764

SEC source: 0001062993-23-006330 · form4.xml · nonDerivative · entry 3

PISKEL KYLE · CIK 0001780662 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,564

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-23-006330 · form4.xml · nonDerivative · entry 2

PISKEL KYLE · CIK 0001780662 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,793

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-23-006330 · form4.xml · nonDerivative · entry 1

PISKEL KYLE · CIK 0001780662 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,093

SEC source: 0001062993-23-006329 · form4.xml · derivative · entry 4

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 128,599

Underlying: Common Stock · 128,599 shares

Expires 2033-03-06

F2 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001062993-23-006329 · form4.xml · nonDerivative · entry 2

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 168,469

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001062993-23-006329 · form4.xml · nonDerivative · entry 1

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 175,285

SEC source: 0001062993-23-006323 · form4.xml · derivative · entry 3

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 199,549

Underlying: Common Stock · 199,549 shares

Expires 2033-03-06

F2 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereunder at the end of each full month of continuous service until fully vested.

SEC source: 0001062993-23-006323 · form4.xml · nonDerivative · entry 2

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 336,824

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by Issuer's election under the equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.